OM336 in Autoimmune Cytopenias
Recruiting
Phase 1
Interventional Study
AIHA - Warm Autoimmune Hemolytic Anemia
AIHA - Cold Autoimmune Hemolytic Anemia
ITP - Immune Thrombocytopenia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 32 (estimated)
- Sponsor
- Lakefront Biotherapeutics West LLC · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
* Active autoimmune cytopenia
* Relapsed/refractory after ≥1 prior treatment
* Body weight ≥ 55 kg
* Willing to comply with and study requirements and procedures
Key Exclusion Criteria:
* Previous treatment with a BCMA-targeted therapy
* Clinically significant infection wi…
Contacts